PSMD1 and Huntington disease: Overall, at 6 months after the second dose of the BNT162b2 vaccine, 83/104 (79.8%) HD Patients maintained seropositivity for an anti-S1 antibody level compared to 83/84 (98.8%) in the control group (p < 0.001).